Medtronic, the global medical device giant, announced the “transcripts†of global mergers and acquisitions in the past year.
Since July 2014, a total of 10 M&A projects have been completed. The business areas include diabetes diagnosis and treatment, vascular embolization, non-invasive cardiac mapping, and hearing material implantation. Such frequent acquisitions have made many industry experts wonder when they are shocked: What kind of chess does Medtronic have in the end?
The picture shows the statistics of mergers and acquisitions of Medtronic in the past year.
In fact, competition among the global medical device industry has become more and more accumulated. The world's top ranked Johnson & Johnson, GE, Philips, Siemens and Medtronic are all competitors. Through the continuous mergers and acquisitions in recent years, Medtronic has already collected dozens of medical device companies, and at the end of 2014, it has taken the top spot in the global medical device industry.
With the rapid development of the global medical device market, the tide of mergers and acquisitions of multinational pharmaceutical companies will continue in the future. Some analysts pointed out that although the medical device business has sprung up in recent years, the advantages of many multinational companies are not very obvious, so business mergers and acquisitions have become their only breakthrough.
Complete 10 mergers and acquisitions a year
Since 2015, Medtronic has made great strides in investing in mergers and acquisitions. Following the completion of Visualase, Reverse Medical, SapiensSteering Brain Stimulation, NGC Medical, and Sapheon in 2014, Medtronic announced in January 2015 that it will acquire Kehui Medical for $42.9 billion, which not only completes the largest acquisition of medical devices worldwide, but also Let it jump beyond the strong generation into the world's largest medical device company.
After that, Medtronic was able to acquire companies such as Aptus Endosystems, CardioInsight Technologies, Sophono, Diabeter, and Advanced Uro-Solution, which enabled the company to gradually expand its business footprint and achieve rapid expansion of its revenue.
Medtronic, which started with a pacemaker, is no longer confined to the heart. According to the editor, Medtronic currently has four lines of business, namely cardiovascular business, diabetes business, restorative therapy business, and Kehui business.
According to the annual report released by Medtronic, revenue for FY2015 was US$20.261 billion, up 6% year-on-year; revenue under non-GAAP was US$4.744 billion, and diluted earnings per share were US$4.28, up 16% and 6% year-on-year respectively. .
“Strong performance not only demonstrates Medtronic’s successful acquisition strategy, but also reflects the three strategies of therapeutic innovation, globalization and economic value.†Medtronic Chairman and CEO Omar Ishrak said that Medtronic will work with partners to The company's services benefit more patients around the world.
But not just mergers and acquisitions, Medtronic's product line will expand even more. On May 15th, Medtronic exhibited a variety of new products such as the leadless pacemaker Micra, the new generation capsule endoscope PillCam, and the Aquamantys RF hemostasis system at the 73rd China International Medical Equipment (Spring) Expo.
Heatless Adsorption Air Dryer,Heatless Air Dryer,Heatless Adsorption Dryer,Heatless Desiccant Dryer
Hangzhou Zhongju air separation equipment manufacturing Co., Ltd , https://www.hzzjkfzz.com